Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Peptic Ulcer

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 38 articles:
HTML format



Single Articles


    November 2021
  1. LOOSEN SH, Kostev K, Luedde M, Qvartskhava N, et al
    Long-term use of proton pump inhibitors (PPIs) is associated with an increased risk of type 2 diabetes.
    Gut. 2021 Nov 1. pii: gutjnl-2021-326297. doi: 10.1136/gutjnl-2021-326297.
    PubMed    


    October 2021
  2. SHAH S, Halvorson A, McBay B, Dorn C, et al
    Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort.
    Gut. 2021 Oct 18. pii: gutjnl-2021-325701. doi: 10.1136/gutjnl-2021-325701.
    PubMed    


    September 2021
  3. GUO CLT, Wong SH, Lau LHS, Lui RNS, et al
    Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-wide cohort study.
    Gut. 2021 Sep 21. pii: gutjnl-2020-323054. doi: 10.1136/gutjnl-2020-323054.
    PubMed     Abstract available


    August 2021
  4. ARAI J, Niikura R, Hayakawa Y, Aoki T, et al
    OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325551. doi: 10.1136/gutjnl-2021-325551.
    PubMed    


    July 2021
  5. PATEL J, Berezowski I, Janapala RN, Pourmand A, et al
    Proton pump inhibitors and gastric cancer: a population-based cohort study.
    Gut. 2021 Jul 14. pii: gutjnl-2021-325385. doi: 10.1136/gutjnl-2021-325385.
    PubMed    


  6. OSTER P, Vaillant L, Riva E, McMillan B, et al
    Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.
    Gut. 2021 Jul 12. pii: gutjnl-2020-323392. doi: 10.1136/gutjnl-2020-323392.
    PubMed     Abstract available


  7. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
    Gut. 2021 Jul 5. pii: gutjnl-2021-325097. doi: 10.1136/gutjnl-2021-325097.
    PubMed     Abstract available


  8. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of colorectal cancer.
    Gut. 2021 Jul 1. pii: gutjnl-2021-325096. doi: 10.1136/gutjnl-2021-325096.
    PubMed     Abstract available


    June 2021
  9. ONG JS, An J, Han X, Law MH, et al
    Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis.
    Gut. 2021 Jun 29. pii: gutjnl-2020-323906. doi: 10.1136/gutjnl-2020-323906.
    PubMed     Abstract available


    May 2021
  10. SEO SI, Park CH, You SC, Kim JY, et al
    Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Gut. 2021 May 11. pii: gutjnl-2020-323845. doi: 10.1136/gutjnl-2020-323845.
    PubMed     Abstract available


    April 2021
  11. MEGRAUD F, Bruyndonckx R, Coenen S, Wittkop L, et al
    Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community.
    Gut. 2021 Apr 9. pii: gutjnl-2021-324032. doi: 10.1136/gutjnl-2021-324032.
    PubMed     Abstract available


    March 2021
  12. SUNG JJY, Laine L, Kuipers EJ, Barkun AN, et al
    Towards personalised management for non-variceal upper gastrointestinal bleeding.
    Gut. 2021 Mar 1. pii: gutjnl-2020-323846. doi: 10.1136/gutjnl-2020-323846.
    PubMed     Abstract available


    December 2020
  13. SPILLER RC, Jalanka J
    Brachyspira and IBS with diarrhoea: a Helicobacter pylori moment?
    Gut. 2020 Dec 24. pii: gutjnl-2020-323370. doi: 10.1136/gutjnl-2020-323370.
    PubMed    


  14. HE Q, Yang M, Qin X, Fan D, et al
    Risk stratification for proton pump inhibitor-associated type 2 diabetes: a population-based cohort study.
    Gut. 2020 Dec 22. pii: gutjnl-2020-323816. doi: 10.1136/gutjnl-2020-323816.
    PubMed    


  15. LU TX, Dapas M, Lin E, Peters T, et al
    The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
    Gut. 2020 Dec 17. pii: gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609.
    PubMed     Abstract available


  16. LEE SW, Yang JM, Yoo IK, Moon SY, et al
    Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort.
    Gut. 2020 Dec 10. pii: gutjnl-2020-323672. doi: 10.1136/gutjnl-2020-323672.
    PubMed    


  17. ZHOU J, Wang X, Lee S, Wu WKK, et al
    Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.
    Gut. 2020 Dec 4. pii: gutjnl-2020-323668. doi: 10.1136/gutjnl-2020-323668.
    PubMed    


    November 2020
  18. LI GF, An XX, Yu Y, Jiao LR, et al
    Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis.
    Gut. 2020 Nov 10. pii: gutjnl-2020-323366. doi: 10.1136/gutjnl-2020-323366.
    PubMed    


    October 2020
  19. LIOU JM, Malfertheiner P, Lee YC, Sheu BS, et al
    Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.
    Gut. 2020 Oct 1. pii: gutjnl-2020-322368. doi: 10.1136/gutjnl-2020-322368.
    PubMed     Abstract available


    September 2020
  20. ZHOU X, Zhu H, Chen Y, Li Z, et al
    Role of Helicobacter pylori in gastric diseases pathogenesis cannot be ignored.
    Gut. 2020 Sep 29. pii: gutjnl-2020-322629. doi: 10.1136/gutjnl-2020-322629.
    PubMed    


  21. YUAN J, He Q, Nguyen LH, Wong MCS, et al
    Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies.
    Gut. 2020 Sep 28. pii: gutjnl-2020-322557. doi: 10.1136/gutjnl-2020-322557.
    PubMed     Abstract available


  22. NYSSEN OP, Bordin D, Tepes B, Perez-Aisa A, et al
    European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.
    Gut. 2020 Sep 21. pii: gutjnl-2020-321372. doi: 10.1136/gutjnl-2020-321372.
    PubMed     Abstract available


  23. GRAHAM DY, El-Serag HB
    European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners.
    Gut. 2020 Sep 21. pii: gutjnl-2020-322385. doi: 10.1136/gutjnl-2020-322385.
    PubMed    


  24. WU CY, Ho HJ, Wu CY, Chen YJ, et al
    Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor.
    Gut. 2020 Sep 9. pii: gutjnl-2020-321932. doi: 10.1136/gutjnl-2020-321932.
    PubMed    


    August 2020
  25. CHIANG TH, Chang WJ, Chen SL, Yen AM, et al
    Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands.
    Gut. 2020 Aug 13. pii: gutjnl-2020-322200. doi: 10.1136/gutjnl-2020-322200.
    PubMed     Abstract available


    July 2020
  26. EUSEBI LH, Cirota GG, Zagari RM, Ford AC, et al
    Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis.
    Gut. 2020 Jul 30. pii: gutjnl-2020-321365. doi: 10.1136/gutjnl-2020-321365.
    PubMed     Abstract available


  27. LEE SW, Ha EK, Yeniova AO, Moon SY, et al
    Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.
    Gut. 2020 Jul 30. pii: gutjnl-2020-322248. doi: 10.1136/gutjnl-2020-322248.
    PubMed     Abstract available


    May 2020
  28. ROGERS BD, Valdovinos LR, Crowell MD, Bell R, et al
    Number of reflux episodes on pH-impedance monitoring associates with improved symptom outcome and treatment satisfaction in gastro-oesophageal reflux disease (GERD) patients with regurgitation.
    Gut. 2020 May 28. pii: gutjnl-2020-321395. doi: 10.1136/gutjnl-2020-321395.
    PubMed     Abstract available


    April 2020
  29. XIONG J, Wang Y, Chen G, Jin L, et al
    Proton pump inhibitors and the risk of gallbladder cancer: a hospital-based case-control study.
    Gut. 2020 Apr 9. pii: gutjnl-2020-321052. doi: 10.1136/gutjnl-2020-321052.
    PubMed    


  30. WONG GLH, Lau LHS, Ching JYL, Tse YK, et al
    Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
    Gut. 2020;69:652-657.
    PubMed     Abstract available


    March 2020
  31. FORD AC, Yuan Y, Moayyedi P
    Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis.
    Gut. 2020 Mar 23. pii: gutjnl-2020-320839. doi: 10.1136/gutjnl-2020-320839.
    PubMed     Abstract available


  32. YAMAJI Y, Hirata Y
    Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?
    Gut. 2020;69:605-606.
    PubMed    


    January 2020
  33. TAO ZH, Fang JY
    The complicated dialogue between Helicobacter pylori and p53.
    Gut. 2020 Jan 23. pii: gutjnl-2020-320630. doi: 10.1136/gutjnl-2020-320630.
    PubMed    


  34. SUNG JJY, Coker OO, Chu E, Szeto CH, et al
    Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication.
    Gut. 2020 Jan 23. pii: gutjnl-2019-319826. doi: 10.1136/gutjnl-2019-319826.
    PubMed     Abstract available


  35. SUZUKI S, Gotoda T, Kusano C, Ikehara H, et al
    Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.
    Gut. 2020 Jan 8. pii: gutjnl-2019-319954. doi: 10.1136/gutjnl-2019-319954.
    PubMed     Abstract available


    December 2019
  36. GUO Y, Zhang Y, Gerhard M, Gao JJ, et al
    Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer.
    Gut. 2019 Dec 19. pii: gutjnl-2019-319696. doi: 10.1136/gutjnl-2019-319696.
    PubMed     Abstract available


  37. COSTA L, Corre S, Michel V, Le Luel K, et al
    USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis.
    Gut. 2019 Dec 10. pii: gutjnl-2019-318640. doi: 10.1136/gutjnl-2019-318640.
    PubMed     Abstract available


    November 2019
  38. TONG H, Lan T, Tang CW
    Prophylactic angiographic embolisation after endoscopic treatment of bleeding for high-risk peptic ulcers: what are the more appropriate indications?
    Gut. 2019 Nov 27. pii: gutjnl-2019-319818. doi: 10.1136/gutjnl-2019-319818.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Peptic Ulcer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: